Olgu Sunumu
BibTex RIS Kaynak Göster

COVID-19 TEDAVİSİNİN NADİR YAN ETKİSİ: FEMUR BAŞI AVASKÜLER NEKROZU

Yıl 2023, Cilt: 37 Sayı: 1, 33 - 37, 28.04.2023

Arda Kaya Hüseyin Aytaç Erdem Dündar Sabah Tansu Yamazhan Meltem Taşbakan

https://doi.org/10.54962/ankemderg.1277280

Öz

2019 yılının son günlerinde, Çin’in Hubei eyaletinden etiyolojisi bilinmeyen ardışık pnömoni vakaları bildirilmeye başlanmış ve daha sonra SARS-CoV2 olarak adlandırılacak olan bu yeni tip Coronavirüs kısa sürede tüm dünyaya hızla yayılarak bir pandemiye dönüşmüştür. Bu süreçte tedavide birçok yeni molekül ile birlikte steroidlerin de kullanım sıklığı artmıştır. Steroidlerin pek çok yan etkisi bulunmaktadır ve femur başı avasküler nekrozu steroidlerin uzun süreli kullanımı sonucu görebildiğimiz önemli yan etkilerinden biridir. Bu yazıda COVID-19 pnömonisi nedeniyle yoğun bakım ünitesi ve ardından serviste izlenen bir hastada kısa süreli steroid kullanımı sonucu gelişen bilateral femur başı avasküler nekrozu olgusu sunulmuştur.

Anahtar Kelimeler

femur başı avasküler nekrozu COVID-19 steroit yan etki

Kaynakça

  • 1. Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med (New York, N.Y.). 2021;2(5):501-4. https://doi.org/10.1016/j.medj.2021.03.003.
  • 2. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124. https://doi.org/10.1053/sarh.2002.33724b
  • 3. Campbell C, Andersson MI, Ansari MA, et al. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era. Front Med. 2021;8:706482. https://doi.org/10.3389/fmed.2021.706482.
  • 4. Fye MA, Huo MH, Zatorski LE, et al. Total hip arthroplasty performed without cement in patients with femoral head osteonecrosis who are less than 50 years old. J Arthroplasty. 1998;13(8):876-81. https://doi.org/10.1016/s0883-5403(98)90193-0.
  • 5. Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-40. https://doi.org/10.1038/s41564-022-01172-2
  • 6. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24. https://doi.org/10.1136/ard.2008.092163
  • 7. Marconi VC, Ramanan AV, de Bono S, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet. 2021;9(12):1407-18. https://doi.org/10.1016/S2213-2600(21)00331-3
  • 8. Mavi D, İnkaya AÇ. COVID-19 İmmün patogenez. FLORA. 2020;25 https://doi.org/ 10.5578/flora.69606
  • 9. Min KH, Rhee CK, Jung JY, et al. Characteristics of adverse effects when using high dose short term steroid regimen. Korean J Audiol. 2012;16(2):65-70. https://doi.org/10.7874/kja.2012.16.2.65
  • 10. Parvizi J, Fassihi SC, Enayatollahi MA. Diagnosis of periprosthetic joint infection following hip and knee arthroplasty. Orthop Clin North Am. 2016;47(3):505-15. https://doi.org/10.1016/j.ocl.2016.03.001
  • 11. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with COVID-19. N England J Med. 2021;384(8):693-704. https://doi.org/10.1056/NEJMoa2021436.
  • 12. Seamon J, Keller T, Saleh J, et al. The pathogenesis of nontraumatic osteonecrosis. Arthritis. 2012;601763. https://doi.org/10.1155/2012/601763
  • 13. Strehl C, Ehlers L, Gaber T, et al. Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. Front Immunol. 2019;10:1744. https://doi.org/10.3389/fimmu.2019.01744.
  • 14. Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI. An update of anti-viral treatment of COVID-19. Turk J Med Sci. 2021;51(SI-1):3372-90. https://doi.org/10.3906/sag-2106-250
  • 15. Tierney Jr. LM, McPhee SJ, Papadakis MA. Current Medical diagnosis and treatment. 36. Baskı, s. 798-799, Stamford: Appleton & Lange, New York (1997).
  • 16. Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019;10:1545. https://doi.org/10.3389/fimmu.2019.01545
  • 17. van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020; 24(1):696. https://doi.org/10.1186/s13054-020-03400-9
  • 18. WHO. COVID-19 Weekly Epidemiological Update 14. Edition 105. 17 August 2022. [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2022]. (Erişim Tarihi: 13/09/2022)
  • 19. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:(6):499-518. https://doi.org/10.1001/jama.2021.11330
  • 20. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo, et al. Repurposed Antiviral Drugs for Covid-19, Interim WHO solidarity trial results. N England J Med. 2021;384(6):497-511. https://doi.org/10.1056/NEJMoa2023184
  • 21. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis. 2001;33(Suppl 2):S94-106. https://doi.org/10.1086/321863
  • 22. Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. 2022 In StatPearls. İnternet adresi: [https://www.ncbi.nlm.nih.gov/books/NBK531462/] Erişim Tarihi: (15/09/2022)

A Rare Side Effect of COVID-19 Treatment: Avascular Femoral Necrosis

Yıl 2023, Cilt: 37 Sayı: 1, 33 - 37, 28.04.2023

Arda Kaya Hüseyin Aytaç Erdem Dündar Sabah Tansu Yamazhan Meltem Taşbakan

https://doi.org/10.54962/ankemderg.1277280

Öz

In the last days of 2019, consecutive pneumonia cases of unknown etiology started to be reported from China's Hubei province, this new type of Coronavirus, which would be named as SARS-CoV2 quickly spread all over the world and turned into a pandemic. During the pandemic, the frequency of use of steroids has increased along with many new molecules in treatment. Steroids have many side effects and, avascular femoral necrosis is one of the important side effects that we can see as a result of long-term use of steroids. In this article, a case of a patient who developed bilateral avascular femoral necrosis as a result of short-term steroid use for COVID-19 pneumonia was presented.

Anahtar Kelimeler

avascular femoral necrosis COVID-19 steroid side effect

Kaynakça

  • 1. Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med (New York, N.Y.). 2021;2(5):501-4. https://doi.org/10.1016/j.medj.2021.03.003.
  • 2. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124. https://doi.org/10.1053/sarh.2002.33724b
  • 3. Campbell C, Andersson MI, Ansari MA, et al. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era. Front Med. 2021;8:706482. https://doi.org/10.3389/fmed.2021.706482.
  • 4. Fye MA, Huo MH, Zatorski LE, et al. Total hip arthroplasty performed without cement in patients with femoral head osteonecrosis who are less than 50 years old. J Arthroplasty. 1998;13(8):876-81. https://doi.org/10.1016/s0883-5403(98)90193-0.
  • 5. Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-40. https://doi.org/10.1038/s41564-022-01172-2
  • 6. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24. https://doi.org/10.1136/ard.2008.092163
  • 7. Marconi VC, Ramanan AV, de Bono S, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet. 2021;9(12):1407-18. https://doi.org/10.1016/S2213-2600(21)00331-3
  • 8. Mavi D, İnkaya AÇ. COVID-19 İmmün patogenez. FLORA. 2020;25 https://doi.org/ 10.5578/flora.69606
  • 9. Min KH, Rhee CK, Jung JY, et al. Characteristics of adverse effects when using high dose short term steroid regimen. Korean J Audiol. 2012;16(2):65-70. https://doi.org/10.7874/kja.2012.16.2.65
  • 10. Parvizi J, Fassihi SC, Enayatollahi MA. Diagnosis of periprosthetic joint infection following hip and knee arthroplasty. Orthop Clin North Am. 2016;47(3):505-15. https://doi.org/10.1016/j.ocl.2016.03.001
  • 11. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with COVID-19. N England J Med. 2021;384(8):693-704. https://doi.org/10.1056/NEJMoa2021436.
  • 12. Seamon J, Keller T, Saleh J, et al. The pathogenesis of nontraumatic osteonecrosis. Arthritis. 2012;601763. https://doi.org/10.1155/2012/601763
  • 13. Strehl C, Ehlers L, Gaber T, et al. Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. Front Immunol. 2019;10:1744. https://doi.org/10.3389/fimmu.2019.01744.
  • 14. Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI. An update of anti-viral treatment of COVID-19. Turk J Med Sci. 2021;51(SI-1):3372-90. https://doi.org/10.3906/sag-2106-250
  • 15. Tierney Jr. LM, McPhee SJ, Papadakis MA. Current Medical diagnosis and treatment. 36. Baskı, s. 798-799, Stamford: Appleton & Lange, New York (1997).
  • 16. Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019;10:1545. https://doi.org/10.3389/fimmu.2019.01545
  • 17. van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020; 24(1):696. https://doi.org/10.1186/s13054-020-03400-9
  • 18. WHO. COVID-19 Weekly Epidemiological Update 14. Edition 105. 17 August 2022. [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2022]. (Erişim Tarihi: 13/09/2022)
  • 19. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:(6):499-518. https://doi.org/10.1001/jama.2021.11330
  • 20. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo, et al. Repurposed Antiviral Drugs for Covid-19, Interim WHO solidarity trial results. N England J Med. 2021;384(6):497-511. https://doi.org/10.1056/NEJMoa2023184
  • 21. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis. 2001;33(Suppl 2):S94-106. https://doi.org/10.1086/321863
  • 22. Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. 2022 In StatPearls. İnternet adresi: [https://www.ncbi.nlm.nih.gov/books/NBK531462/] Erişim Tarihi: (15/09/2022)
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Klinik Tıp Bilimleri, Tıbbi Mikrobiyoloji
Bölüm Olgu Sunumları
Yazarlar

Arda Kaya Bu kişi benim 0000-0003-3491-5412

Hüseyin Aytaç Erdem Bu kişi benim 0000-0001-7375-977X

Dündar Sabah Bu kişi benim 0000-0002-3391-2597

Tansu Yamazhan 0000-0001-5950-0702

Meltem Taşbakan 0000-0002-4689-720X

Yayımlanma Tarihi 28 Nisan 2023
Yayımlandığı Sayı Yıl 2023 Cilt: 37 Sayı: 1

Kaynak Göster

Vancouver Kaya A, Erdem HA, Sabah D, Yamazhan T, Taşbakan M. COVID-19 TEDAVİSİNİN NADİR YAN ETKİSİ: FEMUR BAŞI AVASKÜLER NEKROZU. ANKEM Derg. 2023;37(1):33-7.
 Kapak Resmi İndir

Creative Commons Lisansı
Bu eser Creative Commons Atıf-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.